This study longitudinally analyzed circulating tumor DNA (ctDNA) in 42 patients with advanced melanoma treated with immune checkpoint inhibitors. ctDNA levels significantly correlated with radiological response according to RECIST 1.1 and total tumor volume, especially when measurements were temporally aligned. Although the discriminative performance for identifying progression was moderate, higher ctDNA thresholds demonstrated better specificity. The study also revealed marked heterogeneity in ctDNA shedding across metastatic sites, highlighting its potential as a complementary biomarker for disease monitoring.
This study focuses on developing novel inhibitors targeting the RAS/RAF pathway, a significant challenge in oncology given the frequency of RAS mutations and acquired resistance to existing treatments. Researchers identified small molecules that covalently bind to a distinct site within the RAS-binding domain of RAF, leading to allosteric disruption of its conformation. This mechanism prevents RAS/RAF interaction and downstream signaling. These compounds demonstrated preclinical antitumor efficacy against various cancers with KRAS, NRAS, and HRAS mutations, as well as wild-type RAS-driven cancers. They also suppressed tumor growth in BRAFV600E melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation.
This retrospective study evaluated the efficacy and safety of neoadjuvant immunotherapy in 24 patients with locally advanced resectable melanoma. Treatment primarily involved pembrolizumab monotherapy or a combination of ipilimumab and nivolumab. A pathological complete response (pCR) rate of 16.7% and a pathological partial response (pPR) rate of 33.3% were observed. NRAS codon 61 mutations were present in 42% of patients, with 50% of these achieving a pPR. Toxicity, particularly colitis with combination therapy, represented a significant clinical challenge.